Nystatin is a well-established topical fungicidal agent in the treatment of vaginitis due to Candida albicans (Pace and Schantz, 1956; Chesney, 1956; Rohatiner, 1966) . Amphotericin B is effective in a number of systemic fungal infections and can also be used locally, yet few studies have appeared on its value in Candida vaginitis (Jennison, 1958; Stough and Blank, 1958) and none has been designed to compare the two preparations with each other.
The present report compares the two drugs in Candida infection of the vagina in pregnant and non-pregnant women. Alternate patients were given either nystatin pessaries (two pessaries inserted nightly for 15 days) or amphotericin B pessaries (one pessary inserted nightly for 15 days). It was planned to examine the patients clinically and bacteriologically 2 weeks after the end of treatment and again 4 to 6 weeks later. The criterion of cure was the absence of Candida in two consecutive smears and cultures spread over a period of 6 to 8 weeks after treatment and the absence of vulvovaginitis. The two groups of patients were comparable as regards age; those receiving nystatin had a mean age of 28-3 years (range 17 to 45) and those on amphotericin B a mean age of 25-8 years (range 16 to 44). Eleven of the patients receiving nystatin and twelve of those given amphotericin B were pregnant. * Received for publication February 14, 1967. Results Four of the sixty patients defaulted and are not further considered. The results of treatment are shown in Table I . Patients who did not respond clinically and bacteriologically to the initial course were usually re-treated with the alternative preparation (Table II) . If treatment and re-treatment results are combined, there were seven (25 per cent.) failures in 28 patients given amphotericin B and two (6 per cent.) failures in 35 patients receiving nystatin. One patient failed to respond to both preparations. The results suggest that nystatin is more effective than amphotericin B in the doses given, the difference reaching statistical significance (P=0 = 05) when treated as well as re-treated cases are considered together. Jennison (1958) found that pregnancy greatly reduced the efficacy of amphotericin B but this was not our experience (Table III, Male consorts of four patients with persistent or recurrent Candida vaginitis were examined and one was found to have Candida balanitis, but the possibility of re-infection from this source was denied.
Material and Methods

Discussion
The two dosage schemes were based on the average mean inhibitory concentration of nystatin and amphotericin B against Candida albicans and so adjusted as to give similar fungicidal activity (Jennison and Stenton, 1957; Ewing, 1967) .
The results of the trial indicate that amphotericin B has no obvious advantages over nystatin in the treatment of vaginal candidosis, and as amphotericin B is a potentially life-saving drug in systemic fungal diseases it should not be used in the routine management of trivial infections, even though natural resistance to this drug appears to be remarkably rare (Lampen, 1966 
